



G Medical Innovations Holdings Ltd
ARBN 617 204 743

ASX Announcement

6 April 2020

Prizma device successfully registered with Italian Health Ministry

- **Prizma now registered on Italian Health Ministry Database of medical products**
- **Prizma device can detect and monitor symptoms associated with infection and acute and chronic illness – device has the potential to alleviate pressure on hospitals and clinics**
- **First Prizma units ordered and purchased by Meditel in expedited market initiative**
- **GMV and Meditel confident of significant uptake as demand for telehealth and e-health technologies and services increases**

Mobile and e-Health company **G Medical Innovations (ASX: GMV)** (“**G Medical**” or the “**Company**”) is pleased to advise that its Prizma medical device has been successfully registered with the Italian Health Ministry’s database of medical products (registration number: RDM 1938127). This is a significant achievement for G Medical, as the Prizma device is now approved for distribution and use in Italy.

The Prizma is used by everyday consumers to monitor vital signs including temperature, heart rate, stress levels, SPO₂ (blood oxygen saturation) and electrocardiography (ECG), all of which are physiological biometrics that can be measured to detect symptoms associated with infection and chronic illness.

Italy is currently experiencing significant healthcare challenges and the Company is confident that the Prizma device may assist in alleviating pressure on healthcare systems facing capacity challenges. Through this agreement, G Medical and Meditel are offering and providing access to medically certified devices and unique, sophisticated telehealth technologies and service solutions to assist patients.

G Medical is confident that the Prizma will be well received by consumers and healthcare professionals. The Company will further benefit as more countries push towards telehealth solutions and connected care, in particular consideration of out-of-clinic and isolated vital sign monitoring requirements.

The Company has commenced the fulfilment of Prizma units to Meditel and will update its shareholders on the continued efforts with Meditel and within the Italian territory.

Meditel is a leading European telemedicine provider that delivers telehealth services through web-based call centres in Italy through third party providers. Meditel has activated telemedicine service delivery points in over 500 pharmacies, which are utilised on a pay-per-use basis.

Meditel also owns and operates ‘Lifechart’, a platform used for home monitoring of chronic patients. This web-based service was developed to defray costs for hospitals and healthcare facilities. Lifechart is certified to deliver electrocardiogram (ECG) monitoring services and provides another large opportunity for G Medical.

Delivery of initial devices will commence shortly. G Medical looks forward to working collaboratively with Meditel in the coming weeks to ensure product uptake and considerable in-country growth.

CEO and Executive Director Dr Yacov Geva said: “Receiving the necessary approvals from the Italian Health Ministry unlocks a tremendous opportunity for G Medical and we hope that the Prizma device can assist healthcare providers in treating patients remotely while services are inundated.

“The Company is witnessing an overwhelming increase in demand for telehealth solutions due to the current healthcare challenges being experienced in all parts of the globe and we are confident that upon uptake, G Medical’s products will provide genuine medical value to physicians and patients. We look forward to updating shareholders on progress in the coming weeks.”

Ends

This announcement was authorised for release by Yacov Geva, Managing Director.

Released through: Henry Jordan, Six Degrees Investor Relations: +61 (0) 431 271 538

About G Medical Innovations

G Medical (**ASX: GMV**) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.

The Company specialises in innovative next generation mobile and e-health solutions using its suite of proprietary devices and software solutions, as well as patient service operations, with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.

For more information on G Medical, please visit www.gmedinnovations.com

About G Medical products:

G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals.

The ‘Prizma’ Medical Smartphone Case is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The ‘Prizma’ allows consumers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members.

G Medical also offers a professional real-time patient continuous monitoring solution, G Medical’s Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge home-based settings.